Drug-eluting Balloon Versus Second Generation Drug Eluting Stents in the Treatment of In-stent Restenosis: A Systematic Review and Meta-analysis

Heart Lung and Circulation

Volumn 25, Issue 12, 2016, Pages 1184-1194

  Liou, Kevin ^a,b   Jepson, Nigel ^a,b   Cao, Chris ^c   Luo, Roger ^b   Pala, Sarvpreet ^b   Ooi, Sze Yuan ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

Author keywords

Coronary artery disease; Drug eluting balloon; Drug eluting stent; In stent restenosis; Outcome assessment; Percutaneous coronary intervention

Indexed keywords

CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMAN; MALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84969913331     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2016.04.001     Document Type: Article

References (28)

1. [1] Grüntzig, A.R., Senning, Å., Siegenthaler, W.E., Nonoperative Dilatation of Coronary-Artery Stenosis. N Engl J Med. 301 (1979), 61–68.
2. [2] Sigwart, U., Puel, J., Mirkovitch, V., Joffre, F., Kappenberger, L., Intravascular Stents to Prevent Occlusion and Re-Stenosis after Transluminal Angioplasty. N Engl J Med. 316 (1987), 701–706.
3. [3] Farooq, V., Gogas, B.D., Serruys, P.W., Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv. 4 (2011), 195–205.
4. [4] Cassese, S., Byrne, R.A., Tada, T., Pinieck, S., Joner, M., Ibrahim, T., et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 100 (2014), 153–159.
5. [5] Kastrati, A., Mehilli, J., von Beckerath, N., Dibra, A., Hausleiter, J., Pache, J., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. JAMA. 293 (2005), 165–171.
6. [6] Alfonso, F., Pérez-Vizcayno, M.-J., Hernandez, R., Fernandez, C., Escaned, J., Bañuelos, C., et al. Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: Results of a pooled analysis of two randomized studies. Catheter Cardiovasc Interv. 72 (2008), 459–467.
7. [7] Stone, G.W., Ellis, S.G., O'Shaughnessy, C.D., Martin, S.L., Satler, L., McGarry, T., et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The taxus v ISR randomized trial. JAMA. 295 (2006), 1253–1263.
8. [8] Ribamar Costa, J., Sousa, A., Moreira, A., Alves da Costa, R., Cano, M., Maldonado, G., et al. Comparison of the very long term (>1 year) outcomes of drug-eluting stents for the treatment of bare-metal and drug-eluting stent restenosis. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 5 (2009), 448–453.
9. [9] Lee, J.M., Park, J., Kang, J., Jeon, K.-H., Jung J-h, Lee, S.E., et al. Comparison Among Drug-Eluting Balloon, Drug-Eluting Stent, and Plain Balloon Angioplasty for the Treatment of In-Stent Restenosis: A Network Meta-Analysis of 11 Randomized, Controlled Trials. JACC: Cardiovascular Interventions. 8 (2015), 382–394.
10. [10] Femia, G., Kushwaha, V., Pitney, M., Jepson, N., Initial Experience with Drug-Eluting Balloons in the Treatment of In-Stent Restenosis and de novo Coronary Lesions from Two Combined Public and Private Cardiac Catheterisation Laboratories. Heart Lung Circ, 22(Supplement 1), 2013, S140.
11. [11] Marquis-Gravel, G., Gobeil, F., Noiseux, N., Stevens, L., Mansour, S., Comparison of paclitaxel-eluting balloons with second-generation drug-eluting stents for treatment of in-stent restenosis: a retrospective analysis of an all-comers cohort. J Am Coll Cardiol., 62, 2013, B138.
12. [12] Adriaenssens, T., Dens, J., Ughi, G., Bennett, J., Dubois, C., Sinnaeve, P., et al. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial. EuroIntervention. 10 (2014), 439–448.
13. [13] Alfonso, F., Perez-Vizcayno, M.J., Cardenas, A., Garcia Del Blanco, B., Seidelberger, B., Iniguez, A., et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 63 (2014), 1378–1386.
14. [14] Almalla, M., Schroder, J., Pross, V., Marx, N., Hoffmann, R., Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis. Catheter Cardiovasc Interv. 83 (2014), 881–887.
15. [15] Naganuma, T., Latib, A., Costopoulos, C., Oreglia, J., Testa, L., De Marco, F., et al. Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. EuroIntervention. 11 (2016), 989–995.
16. [16] Kubo, S., Kadota, K., Otsuru, S., Hasegawa, D., Habara, S., Tada, T., et al. Everolimus-eluting stent implantation versus repeat paclitaxel-coated balloon angioplasty for recurrent in-stent restenosis lesion caused by paclitaxel-coated balloon failure. EuroIntervention. 10 (2015), e1–e8.
17. [17] Alfonso, F., Perez-Vizcayno, M.J., Cardenas, A., Garcia Del Blanco, B., Garcia-Touchard, A., Lopez-Minguez, J.R., et al. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. J Am Coll Cardiol. 66 (2015), 23–33.
18. [18] Alfonso, F., Perez-Vizcayno, M.J., Dutary, J., Zueco, J., Cequier, A., Garcia-Touchard, A., et al. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc Interv. 5 (2012), 728–737.
19. [19] Waksman, R., Pakala, R., Drug-eluting balloon: the comeback kid?. Circ Cardiovasc Interv. 2 (2009), 352–358.
20. [20] Axel, D.I., Kunert, W., Göggelmann, C., Oberhoff, M., Herdeg, C., Küttner, A., et al. Paclitaxel Inhibits Arterial Smooth Muscle Cell Proliferation and Migration In Vitro and In Vivo Using Local Drug Delivery. Circulation. 96 (1997), 636–645.
21. [21] Scheller, B., Speck, U., Abramjuk, C., Bernhardt, U., Bohm, M., Nickenig, G., Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 110 (2004), 810–814.
22. [22] Scheller, B., Hehrlein, C., Bocksch, W., Rutsch, W., Haghi, D., Dietz, U., et al. Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter. N Engl J Med. 355 (2006), 2113–2124.
23. [23] Byrne, R.A., Neumann, F.-J., Mehilli, J., Pinieck, S., Wolff, B., Tiroch, K., et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. The Lancet. 381 (2013), 461–467.
24. [24] Buszman, P., Milewski, K., Pajak, J., Jelonek, M., Orlik, B., Krauze, A., et al. Differences in vessel healing following delivery of everolimus or paclitaxel: a comparative experimental study using identical stent and biodegradable polymer platforms. EuroIntervention. 10 (2014), 724–731.
25. [25] Schomig, A., Dibra, A., Windecker, S., Mehilli, J., Suarez de Lezo, J., Kaiser, C., et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 50 (2007), 1373–1380.
26. [26] Habara, S., Kadota, K., Shimada, T., Ohya, M., Amano, H., Izawa, Y., et al. Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis. J Am Coll Cardiol. 66 (2015), 14–22.
27. [27] Garg, S., Serruys, P.W., Coronary stents: current status. J Am Coll Cardiol. 56 (2010), S1–S42.
28. [28] Byrne, R., Cassese, S., Windisch, T., King, L., Joner, M., Tada, T., et al. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. EuroIntervention. 9 (2013), 797–802.